Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): findings from Cohort 2 of MODUL - Grothey, A; Tabernero, J; Arnold, D (2018)
suppl (proffered paper)